Clinical Trial Update: A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This entry reports a Phase 1/2 clinical trial evaluating Lenti-HPV-07 immunotherapy for HPV-associated cervical cancer and HPV-positive oropharyngeal squamous c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Lenti-HPV-07

Snippet

Sponsor: Theravectys S.A. | Conditions: HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING